HK1206600A1 - Use of 2-methylene-19-nor-(20s)-1,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism 2--19--(20s)-125- d3 - Google Patents

Use of 2-methylene-19-nor-(20s)-1,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism 2--19--(20s)-125- d3

Info

Publication number
HK1206600A1
HK1206600A1 HK15107093.4A HK15107093A HK1206600A1 HK 1206600 A1 HK1206600 A1 HK 1206600A1 HK 15107093 A HK15107093 A HK 15107093A HK 1206600 A1 HK1206600 A1 HK 1206600A1
Authority
HK
Hong Kong
Prior art keywords
dihydroxyvitamin
methylene
secondary hyperparathyroidism
treat secondary
treat
Prior art date
Application number
HK15107093.4A
Other languages
English (en)
Chinese (zh)
Inventor
Hector F Deluca
Lori A Plum
Julia B Zella
Margaret Clagett-Dame
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1206600(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of HK1206600A1 publication Critical patent/HK1206600A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15107093.4A 2012-06-29 2015-07-24 Use of 2-methylene-19-nor-(20s)-1,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism 2--19--(20s)-125- d3 HK1206600A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666264P 2012-06-29 2012-06-29
PCT/US2013/031574 WO2014003849A1 (en) 2012-06-29 2013-03-14 USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM

Publications (1)

Publication Number Publication Date
HK1206600A1 true HK1206600A1 (en) 2016-01-15

Family

ID=47997980

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107093.4A HK1206600A1 (en) 2012-06-29 2015-07-24 Use of 2-methylene-19-nor-(20s)-1,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism 2--19--(20s)-125- d3

Country Status (19)

Country Link
US (4) US9205096B2 (xx)
EP (1) EP2866811A1 (xx)
JP (1) JP2015522015A (xx)
KR (1) KR20150030673A (xx)
CN (1) CN104394871A (xx)
AU (1) AU2013281217B2 (xx)
BR (1) BR112014032847A2 (xx)
CA (1) CA2877680C (xx)
CL (1) CL2014003565A1 (xx)
CO (1) CO7240358A2 (xx)
HK (1) HK1206600A1 (xx)
IL (1) IL236184A0 (xx)
MX (1) MX2015000076A (xx)
MY (1) MY172886A (xx)
NZ (1) NZ703347A (xx)
RU (1) RU2666995C2 (xx)
SG (1) SG11201408731WA (xx)
WO (1) WO2014003849A1 (xx)
ZA (1) ZA201500119B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ703347A (en) * 2012-06-29 2016-05-27 Wisconsin Alumni Res Found Use of 2-methylene-19-nor-(20s)-1α,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism
ES2774965T3 (es) 2013-09-27 2020-07-23 Codexis Inc Modelado predictivo a base de estructura
ES2693150T3 (es) 2013-09-27 2018-12-07 Codexis, Inc. Filtración automática de variantes de enzimas
CN103533522A (zh) * 2013-10-25 2014-01-22 从兴技术有限公司 短信稽核的方法及系统
SG11201700858RA (en) * 2014-08-07 2017-03-30 Opko Ireland Global Holdings Ltd Adjunctive therapy with 25-hydroxyvitamin d
US9539264B2 (en) 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
US10369161B2 (en) 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
US10105375B2 (en) 2016-08-30 2018-10-23 Wisconsin Alumni Research Foundation Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043971A1 (en) 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US6306844B1 (en) 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6136799A (en) 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations
US6673782B2 (en) 1999-04-29 2004-01-06 Wisconsin Alumni Research Foundation Treatment of systemic lupus erythematosis
JP2003528833A (ja) 2000-03-27 2003-09-30 ウイスコンシン アラムナイ リサーチ フオンデーシヨン 腎移植体安定化用のビタミンｄ化合物
NZ537036A (en) 2000-07-14 2006-07-28 Wisconsin Alumni Res Found Use of 2-methylene-19-nor-20(S)-1alpha,25-dihydroxyvitamin D3 to increase bone strength
US20080249068A1 (en) 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
US20060171983A1 (en) 2003-07-30 2006-08-03 Jin Tian Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease
MXPA06002947A (es) * 2003-09-19 2006-05-31 Pfizer Prod Inc Derivados de 2-alquilideno-19-nor-vitamina d para el tratamiento de la fragilidad, dano muscular o sarcopenia.
US7704980B2 (en) 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
US7214671B2 (en) 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
AU2006213727B2 (en) 2005-02-11 2011-08-18 Wisconsin Alumni Research Foundation 2-methylene-19-nor- (20S-24S) - 1alpha, 25-dihydroxyvitamin-D2
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
AU2010281391B2 (en) * 2009-08-03 2015-05-07 Wisconsin Alumni Research Foundation Method of preventing renal disease and treating symptoms thereof
CA2794006C (en) 2010-03-23 2017-11-28 Wisconsin Alumni Research Foundation (20s)-2-methylene-19-nor-22-dimethyl-1.alpha.,25-dihydroxyvitamin d3 and (20r)-2-methylene-19-nor-22-dimethyl-1.alpha.,25-hydroxyvitamin d3
NZ703347A (en) * 2012-06-29 2016-05-27 Wisconsin Alumni Res Found Use of 2-methylene-19-nor-(20s)-1α,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism

Also Published As

Publication number Publication date
US9034853B2 (en) 2015-05-19
WO2014003849A1 (en) 2014-01-03
US20160136184A1 (en) 2016-05-19
IL236184A0 (en) 2015-01-29
US10046000B2 (en) 2018-08-14
RU2666995C2 (ru) 2018-09-13
ZA201500119B (en) 2017-11-29
EP2866811A1 (en) 2015-05-06
MX2015000076A (es) 2015-04-10
SG11201408731WA (en) 2015-01-29
US9717744B2 (en) 2017-08-01
CA2877680A1 (en) 2014-01-03
MY172886A (en) 2019-12-13
US20170252360A1 (en) 2017-09-07
CN104394871A (zh) 2015-03-04
CL2014003565A1 (es) 2015-08-28
RU2015102831A (ru) 2016-08-20
CA2877680C (en) 2017-08-29
US9205096B2 (en) 2015-12-08
AU2013281217B2 (en) 2017-03-02
US20140005152A1 (en) 2014-01-02
KR20150030673A (ko) 2015-03-20
US20140187522A1 (en) 2014-07-03
AU2013281217A1 (en) 2015-01-22
BR112014032847A2 (pt) 2017-06-27
NZ703347A (en) 2016-05-27
JP2015522015A (ja) 2015-08-03
CO7240358A2 (es) 2015-04-17

Similar Documents

Publication Publication Date Title
HK1206600A1 (en) Use of 2-methylene-19-nor-(20s)-1,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism 2--19--(20s)-125- d3
ZA201307367B (en) Method of securing non-native code
ZA201406073B (en) Tetramerisation of ethylene
EP2924147A4 (en) PHOTOCHEMICAL REACTION SYSTEM
EP2812777A4 (en) STRING COMPLETION
EP2914098A4 (en) EMERGENCY LINE
GB201201566D0 (en) New chemical compounds
EP2861085A4 (en) NANOSYSTEMS FOR FORMULATING EFFICIENT BIOCIDES WITH MINIMAL RISK
ZA201406074B (en) Tetramerisation of ethylene
ZA201503155B (en) Post-treatment of deboronated mww zeolite
IL229520B (en) Water treatment, especially for obtaining highly purified water
IL237483A0 (en) Preparations for the treatment of psoriasis
EP2937219A4 (en) PRINTER MASSICOT
HUE045685T2 (hu) Triacil-glicerideket tartalmazó olajok konverziója
EP2884975A4 (en) METHOD OF TREATING ONYCHOMYCOSIS
GB201309274D0 (en) Treatment Of Fuel
GB201222683D0 (en) Chemical reactor
LT2895177T (lt) Humuso rūgšties panaudojimas šiltakraujų gyvūnų gydymui
EP3240549A4 (en) Use of 2-methylene-19-nor-(20s)-1a,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism
EP2881717A4 (en) STRUCTURE FOR MASKS
PL2859647T3 (pl) Ruchoma platforma produkcji elektryczności w trybie awaryjnym lub jako skrajnej końcówki
EP2852411A4 (en) ANTI-CCL2 ANTIBODIES FOR THE TREATMENT OF SCLEROMERMIA
GB2515701B (en) Safety scalpel
EP2802549A4 (en) REAKTORPASSIVIERUNGSVERFAHREN
GB201220869D0 (en) Process for sysnthesis of C2-substitutes analogues of 1a,25-dihydroxyvitamin D3